A prospective study assessing safety and tolerability of atezolizumab (anti-programmed death-ligand 1) in combination with trimodal therapy in patients with localized MIBC (Muscle-Invasive Bladder Cancer)
Latest Information Update: 07 Oct 2021
At a glance
- Drugs Atezolizumab (Primary) ; Gemcitabine
- Indications Bladder cancer
- Focus Adverse reactions
- 07 Oct 2021 New trial record